technically I agree, phase II is not phase III. for this phase II trial Primary Outcome Measures: * Progression-free survival status [ Time Frame: 5.5mo ] [ Designated as safety issue: No ]
Dendreon won because the median survival time for Provenge patients was 25.8 months comparing to 21.7 months for placebo-treated patients i.e. +22% If we see +22% survival time for Drug: PF-04948568 (CDX-110) with GM-CSF against comparator Drug: temozolomide I think it will be very good results. CLDX treatment is much cheaper than Provenge. CDX-110 designed for Glioblastoma Multiforme, but they can attach the antigen prostatic acid phosphatase (PAP) to their antibodies and test them on prostate cancer.